News | News By Subject | News by Disease News By Date | Search News

Meningitis, cryptococcal News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
GlaxoSmithKline (GSK) Divests Two Meningitis Drugs to Pfizer (PFE) for $130 Million     6/23/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Pfizer Inc. (PFE) Touts Phase 2 Data For Investigational Meningococcal B Vaccine     5/9/2014
FDA Grants Breakthrough Status Designation To Novartis AG (NVS)' Meningitis B Vaccine     4/8/2014
In a Phase II Study, Novartis Corporation (NVS) Meningitis B Vaccine Has Potential to Produce a Protective Immune Response in Infants, the Age Group Most at Risk     5/14/2008
Novartis Corporation (NVS) Menveo(R) Vaccine Shows Superior Immune Response Against Four Types of Meningitis Disease in Pivotal Phase III Trial     5/6/2008
ID Biomedical (IDBE) Receives Positive Data From Clinical Testing Of Its Group-Common Pneumococcal Vaccine     3/22/2005
Sanofi Pasteur (SASY.PA) Release: FDA Licenses Menactra(TM) (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) For Protection Against Meningococcal Disease     1/17/2005
Advisory Panel Recommends FDA Licensure Of Aventis Pasteur's Menactra(TM) Vaccine For Protection Against Meningococcal Disease     9/23/2004

News from Around the Web

Press Releases
Matinas BioPharma Announces Presentation Of Cryptococcal Meningitis Preclinical Data Of MAT2203 At AIDS-Associated Mycosis Meeting 2016     7/13/2016
Viamet And Mycoses Study Group Education & Research Consortium Establish Collaboration To Advance A Novel Therapy For Cryptococcal Meningitis     8/26/2015
U.S. CDC Recommends Cautious Approach To GlaxoSmithKline (GSK), Pfizer (PFE) Meningitis B Vaccine     6/25/2015
Viamet Pharmaceuticals Receives Orphan Drug Designation For VT-1129     9/11/2014
XOMA (US) LLC (XOMA)'s NEUPREX(R) Granted Orphan Status In Europe; XOMA Proceeding With Marketing Assessment     9/6/2006
NeuTec Pharma plc (NTP.L) Interim Results For The Six Months Ended 31 December 2004     3/14/2005
Shire Pharmaceuticals Group PLC (SHPGY) Release: Health Canada Approves A New Two-Dose Regimen Of NeisVac-C To Protect Against MeningitiS C - Reducing Vaccination Burden In Infants     5/5/2004

//-->